Breaking Down Krishna Institute of Medical Sciences Limited Financial Health: Key Insights for Investors

Investors looking to decode Krishna Institute of Medical Sciences Limited's financial pulse will find plenty to scrutinize: Q4 FY25 revenue hit ₹801 crore (YoY +25.7%, QoQ +1.4%) and FY25 revenue rose to ₹3,067 crore (+22.0%), while Q2 FY26 revenue accelerated to ₹965 crore (YoY +23.3%, QoQ +9.8%) with ARPOB of ₹42,016; profitability shows mixed signals-Q4 FY25 EBITDA stood at ₹203 crore (margin 25.3%) and FY25 EBITDA at ₹815 crore (margin 26.6%) but Q2 FY26 EBITDA slipped 6.7% YoY to ₹208 crore (margin 21.6%) and PAT fell to ₹72 crore (7.5% margin); balance-sheet dynamics reveal net worth of ₹2,097 crore versus gross debt including leases of ₹2,557 crore, long-term debt rising to ₹1,776 crore and gearing up to 1.22x with debt/EBITDA at 3.2x as the company budgets ₹2,200-2,500 crore capex for FY26-28; liquidity remains manageable with cash at ₹120 crore in Q2 FY26 and healthy current/quick ratios even as new-unit ramp-ups and a slower Telangana cluster test near-term margins; market confidence is visible in a market cap of ₹305.6 billion, YTD stock gain of 26.80% and 1-year surge of 78.38%, underpinning analysts' Buy stance and a ₹840 target (30x EV/EBITDA for Sep‑2027) - read on to unpack each metric, stress-test the risks and weigh the growth runway from 2,000 planned beds and oncology rollouts across the next few years

Krishna Institute of Medical Sciences Limited (KIMS.NS) - Revenue Analysis

• Q4 FY25 revenue: ₹801 crore - up 25.7% YoY and 1.4% QoQ.
• Full FY25 revenue: ₹3,067 crore - up 22.0% YoY versus FY24.
• Q2 FY26 revenue: ₹965 crore - up 23.3% YoY and 9.8% QoQ.
• ARPOB in Q2 FY26: ₹42,016, indicating steady revenue per bed improvement.
• New unit ramp-ups continue to add revenue but depress near-term profitability due to start-up costs and lower initial utilisation.
• Telangana cluster: mature market with slower growth compared to newer/geography-diverse clusters.

• Volume and case-mix: Higher speciality volumes and improved case-mix pushed ARPOB higher, supporting margin recovery over mature baselines.
• Geographic mix: Faster growth outside Telangana offset slower expansion in the mature Telangana cluster.
• New hospitals/units: Contributed to revenue growth but caused short-term margin dilution until utilisation ramps.
• Operational focus: Management initiatives targeted ARPOB improvement, bed-turn optimisation and speciality penetration to maximize existing asset productivity.

Krishna Institute of Medical Sciences Limited (KIMS.NS) - Profitability Metrics

• Q4 FY25: EBITDA ₹203 crore (24.4% YoY growth); EBITDA margin 25.3%.
• FY25 (year ending Mar‑2025): EBITDA ₹815 crore (24.7% YoY growth); EBITDA margin 26.6%.
• Q2 FY26: EBITDA ₹208 crore (down 6.7% YoY); EBITDA margin 21.6%.
• Q4 FY25: PAT ₹106 crore (47.2% YoY growth); PAT margin 13.3%.
• FY25: PAT ₹415 crore (23.5% YoY growth); PAT margin 13.5%.
• Q2 FY26: PAT ₹72 crore (down 40.3% YoY); PAT margin 7.5%.

• FY25 demonstrated strong operating leverage: double‑digit EBITDA growth (24.7%) with expansion of EBITDA margin to 26.6%, translating into robust PAT growth (23.5%) and a high PAT margin (13.5%).
• Sequential/early‑FY26 softness: Q2 FY26 shows margin compression (EBITDA margin down to 21.6%) and a steep PAT decline (‑40.3% YoY), indicating either cost pressures, revenue mix shifts, or one‑off items affecting near‑term profitability.
• The divergence between FY25 strength and Q2 FY26 weakness underscores the importance of monitoring quarterly operating trends, bed/occupancy metrics, and cost controls to assess sustainability of margins.

Krishna Institute of Medical Sciences Limited (KIMS.NS) - Debt vs. Equity Structure

• Equity cushion: Net worth of ₹2,097 crore provides a base to support higher borrowings while preserving solvency headroom.
• Debt build-up: Long-term borrowings rose to ₹1,776 crore (up ₹821 crore YoY), reflecting funding for capacity expansion and brownfield/greenfield projects.
• Lease obligations: Lease liabilities increased to ₹651 crore, amplifying total leverage when added to financial debt-total debt including leases is ₹2,557 crore.
• Leverage metrics: Gearing increased to 1.22x from 0.73x; debt/EBITDA moved to 3.2x from 2.1x, indicating higher fixed-charge burden and reduced cushion for earnings volatility.

• Cash flow sensitivity - higher interest and lease payments increase reliance on stable operating cash flows and occupancy/ARPU trends.
• Refinancing and cost of debt - maturity profile and interest rate sensitivity will determine near-term funding risk; capex plan may require additional debt or equity raises.
• Return on invested capital - incremental projects funded by debt must generate returns above blended cost of capital to avoid EPS dilution and protect credit metrics.
• Optionality - the equity base (₹2,097 crore) allows room for alternative financing (equity, JV, asset monetization) to moderate further leverage if needed.

• Planned capex of ₹2,200-2,500 crore (FY2026-2028) implies continued pressure on balance sheet and potential additional borrowing depending on internal accruals and strategic financing choices.
• As debt/EBITDA approaches mid-3x territory, covenant monitoring and liquidity maintenance become more critical for management and lenders.
• Investors should track quarterly trends in EBITDA, free cash flow, capex spend cadence, and any equity issuance or asset-sale programs to assess trajectory of leverage.

Krishna Institute of Medical Sciences Limited (KIMS.NS) - Liquidity and Solvency

• Cash & cash equivalents: ₹112 crore (Q3 FY25) → ₹120 crore (Q2 FY26)
• Current ratio: ~1.6x (reflects adequate short-term assets vs. liabilities)
• Quick ratio: ~1.2x (indicates sufficient immediate liquidity excluding inventory)
• Operating cash flow (TTM): ~₹95 crore (positive but partially absorbed by capex & ramp-up costs)
• Short-term borrowings: ~₹85 crore (manageable within current liquidity profile)

• Positive cash balance provides headroom to fund near-term operations and phased expansion without urgent refinancing.
• Current and quick ratios suggest the company can meet short-term obligations, though metrics should be tracked quarter-to-quarter during ramp-ups.
• Incremental capex and working-capital needs for new units compress margins in the short term; sustained positive operating cash flow is critical until new centers scale.
• The Telangana cluster-being a mature market-showed slower revenue growth relative to newer clusters, shifting contribution growth to other regions.

Krishna Institute of Medical Sciences Limited (KIMS.NS) - Valuation Analysis

• Market capitalization: ₹305.6 billion - signaling strong investor confidence in the company's market position.
• Share-price performance: Year-to-date gain of 26.80%; one-year return of 78.38% - materially outperforming the Sensex over the same periods.
• Analyst stance: Maintained "Buy" rating with a target price of ₹840 per share based on a 30x EV/EBITDA multiple applied to September 2027 estimated EBITDA.
• P/E ratio: Serves as the market's barometer of expected future earnings growth (read alongside EV/EBITDA for capital-structure-neutral valuation).
• EV/EBITDA: The chosen 30x multiple for 2027 estimates underpins the target price and encapsulates expectations for sustained margin and revenue expansion in the healthcare segment.

• The 30x EV/EBITDA multiple used by analysts implies confidence in KIMS.NS's ability to scale earnings and sustain margins in the coming years given its asset-light service mix and regional scale.
• Relative valuation considerations: investors should compare the implied multiples to peer hospitals and broader healthcare services to gauge premium/discount justified by growth, margins, and return on capital.
• Market-cap and price momentum are consistent with a growth-premium narrative, but valuation sensitivity to EBITDA assumptions means the target price is contingent on execution and sector dynamics.

Krishna Institute of Medical Sciences Limited (KIMS.NS) - Risk Factors

• New-unit ramp-up risk: recent additions to capacity have underperformed initial utilization targets, pressuring consolidated margins and delaying expected payback periods.
• Regional growth dispersion: the Telangana cluster - a mature market for KIMS.NS - recorded slower revenue and volume growth versus newer clusters, reducing aggregate same-store growth.
• Rising leverage: the consolidated debt-to-EBITDA ratio increased to 3.2x (from 2.1x), signalling elevated financial risk and less headroom for cyclical downturns.
• Higher gearing: the gearing ratio moved to 1.22x from 0.73x, reflecting greater reliance on debt financing and increased interest-service sensitivity.
• Planned capex burden: management expects capital expenditures of ₹2,200-2,500 crore between FY2026 and FY2028 to fund new hospitals and expansions; this could elevate debt levels or require equity/alternative funding.
• Valuation and analyst stance: most sell-side analysts maintain a 'Buy' rating with a target price of ₹840 per share, which is derived from applying a 30x EV/EBITDA multiple to September 2027 EBITDA estimates - sensitive to execution and margin recovery.

• Key sensitivity drivers investors should monitor:
  • Utilization ramp timelines for new hospitals and their contribution to consolidated EBITDA.
  • Quarterly trend in debt-to-EBITDA and interest coverage ratios.
  • Execution against the ₹2,200-2,500 crore capex plan and the resulting funding mix (debt vs. equity vs. internal accruals).
  • Regional performance divergence, particularly recovery or further deceleration in the Telangana cluster.

Krishna Institute of Medical Sciences Limited (KIMS.NS) - Growth Opportunities

Krishna Institute of Medical Sciences Limited (KIMS.NS) is executing an aggressive capacity and service expansion plan that materially shapes its medium‑term financial trajectory. Key initiatives and targets signal a meaningful uplift in scale, margins and returns for investors willing to look through near‑term investment outlays.

• Capacity expansion: plan to add ~2,000 beds and roll out dedicated oncology departments across hospitals between fiscals 2026-2028.
• Greenfield commercialization: on track to commercialize Bengaluru greenfield expansions by Q2 FY26, unlocking incremental revenue from a high‑ARPOB (average revenue per occupied bed) market.
• Leadership & execution: new leadership hires across Karnataka and Kerala to accelerate cluster ramp‑up and operational control.
• Margin targets: company aims to achieve faster breakeven and >25% operating profit margin across Maharashtra, Karnataka and Kerala clusters over the next 4-5 years.
• Analyst expectations: consensus modelling implies a c.25% EBITDA CAGR over FY25-28E with healthy return ratios (~20%).
• Valuation: current market valuation incorporates growth runway and sector positioning; investors should weigh expansion capex against projected margin uplift and returns.

Investor implications include near‑term capex and ramp costs versus medium‑term margin and return expansion driven by higher bed capacity, oncology offerings and cluster efficiencies. For corporate purpose and guiding principles see: Mission Statement, Vision, & Core Values (2026) of Krishna Institute of Medical Sciences Limited.